摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glenmark pharmaceuticals limited - mometasonum furoatum - spray nazal, suspensie - 50 mcg/doză

摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glenmark pharmaceuticals limited - salmeterolum + fluticasonum - suspensie de inhalat presurizată - 25 mcg/250 mcg/doză

摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glenmark pharmaceuticals limited - salmeterolum + fluticasonum - suspensie de inhalat presurizată - 25 mcg/125 mcg/doză

摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glenmark pharmaceuticals limited - salmeterolum + fluticasonum - suspensie de inhalat presurizată - 25 mcg/50 mcg/doză

罗马尼亚 - 罗马尼亚文 - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

delorbis pharmaceuticals ltd - cipru - posaconazolum - compr. gastrorez. - 100mg - antimicotice de uz sistemic derivati de triazol

罗马尼亚 - 罗马尼亚文 - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

porton biopharma limited - irlanda - asparaginazum - pulb. pt. sol. inj./perf. - 10.000e - antineoplazice alte antineoplazice

罗马尼亚 - 罗马尼亚文 - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmadox healthcare ltd - malta - combinatii (emtricitabinum+tenofovirum) - compr. film. - 200mg/245mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenți antineoplazici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

摩尔多瓦 - 罗马尼亚文 - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sun pharmaceutical industries ltd. - desloratadinum - comprimate filmate - 5 mg

欧盟 - 罗马尼亚文 - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.